The Wall Street Journal: Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market

United States

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $ 10 billion, according to people familiar with the matter.

The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.